Health Care/Hospital News & Press Release Distribution

Health Care/Hospital

APAC
Global

Hummingbird Bioscience Announces HMBD-002 Trials in Progress Poster at ASCO Annual Meeting 2023

* HMBD-002, a non-depleting, high-affinity anti-VISTA antibody, possesses key design features enabling robust anti-tumor activity in preclinical models, positioning it as a potentially important new therapy for VISTA-expressing cancers including triple-negative breast cancer and non-small cell ...

2023-05-29 18:30 2706

AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

HIGHLIGHTS * Amplia's highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer * FOLFIRINOX is the most widely used treatment for pancreatic cancer patients in the US,Canada and most European countries * T...

2023-05-29 16:51 2547

Collaborators at the Keio and Osaka Universities Present Key Non-Clinical Data with Stable/Functional-Induced Regulatory T Cells (S/F-iTregs) in Autoimmune Disease Models

OSAKA, Japan, May 29, 2023 /PRNewswire/ -- RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting. Their presentation demonstrated that in a murine pemphigus model, S/F-iTregs significantly decreased clinical scores, circulating ant...

2023-05-29 13:21 1775

Kosme Aesthetics Celebrates the Opening of its Modern Aesthetic Salon at Plaza Singapura, Orchard Road, Offering a Comprehensive Range of Signature Treatments

SINGAPORE, May 29, 2023 /PRNewswire/ -- Kosme Aesthetics, a renowned provider of state-of-the-art aesthetic treatments inSingapore, is excited to announce the opening of its new salon at Plaza Singapura, #04-08D, Orchard Road. The contemporary facility showcases the brand's dedication to offering...

2023-05-29 11:10 1846

APPLICATION OF HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT: EXPERIENCE FROM THE WORLD AND SITUATION IN VIETNAM

HO CHI MINH CITY, Vietnam, May 29, 2023 /PRNewswire/ -- In the limited medical sources circumstance, the technology evaluation will help policymakers choose and establish the most appropriate health technology coordinating with conditions and actual occurrences, thereby ensuring the best medical ...

2023-05-29 11:00 2060

APPLICATION OF HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT: EXPERIENCE FROM THE WORLD AND SITUATION IN VIETNAM

Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

* Porustobart in combination of toripalimab showed promising anti-tumor activity * Porustobart in combination of toripalimab showed acceptable safety profile in HCC * Porustobart in combination of toripalimab showed favorable PK/PD signature CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZH...

2023-05-29 09:42 2077

77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting

SHANGHAI, May 28, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that the updated results of Phase Ib study of its CSF-1R inhibitor Pimicotinib (ABSK021) in treating patients with advanced tenosynovial giant cell tumor ("TGCT"), will be rele...

2023-05-28 21:00 2748

77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting

Nasdaq Deficiency Letter

NEW YORK, May 27, 2023 /PRNewswire/ -- On May 18, 2023, Etao International Co., Ltd. (the "Company") received a deficiency letter from The Nasdaq Stock Market, LLC ("Nasdaq") notifying the Company that it no longer complies with Nasdaq's Listing Rule 5250(c)(1) due to its failure to file Form 20-...

2023-05-27 05:42 4589

Pulse Medical receives FDA Breakthrough Device Designation for its μFR® system

SHANGHAI, May 26, 2023 /PRNewswire/ -- Pulse Medical Technology, Inc. (Pulse Medical) 4th generation μFR® system has received an FDA Breakthrough Device designation. Pulse Medical, founded in 2015, located in Shanghai, China, is dedicated to developing innovative technology for precise diagnosi...

2023-05-26 22:08 3725

E-Home Household Services Holdings Limited Announces Half-Year Results Ended December 31, 2022

FUZHOU, China, May 26, 2023 /PRNewswire/ -- E-Home Household Service Holdings Limited (Nasdaq: EJH) (the "Company" or "E-Home"), a provider of integrated household services inChina, today announced its financial results for the six months endedDecember 31, 2022. Financial Highlight * Total re...

2023-05-26 21:06 5222

Yili's Subsidiary Westland Milk Products Holds Groundbreaking Ceremony for Lactoferrin Plant in New Zealand

HOKITIKA, New Zealand, May 26, 2023 /PRNewswire/ -- On May 23, Yili's subsidiary Westland Milk Products held a groundbreaking ceremony for the construction of itsNZD 70 million (USD 42.58 million) lactoferrin plant at Hokitika,New Zealand. The ceremony was attended by New Zealand's Trade, Export ...

2023-05-26 20:56 3545

Yili's Subsidiary Westland Milk Products Holds Groundbreaking Ceremony for Lactoferrin Plant in New Zealand

Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023

* ORSERDU (elacestrant) was approved by the FDA in January 2023 for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer withESR1-mutations (ESR1-mut) that are found in up to 40% of tumors * In patients whose tumors har...

2023-05-26 20:37 2597

ProfoundBio Announces Further Advancement of Lead Programs - PRO1184 (Rinatabart Sesutecan) and PRO1160 in the Clinic

* PRO1160 first patient dosed in the US * China NMPA clearance for PRO1184 (rinatabart sesutecan, Rina-S) and PRO1160 to initiate clinical trials * Rina-S preliminary clinical data is encouraging SUZHOU, China and WOODINVILLE, Wash., May 26, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage...

2023-05-26 20:00 2092

Waterdrop Inc. to Report First Quarter 2023 Financial Results on June 5, 2023

BEIJING, May 26, 2023 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH ) ("Waterdrop" or the "Company"), a leading technology platform de...

2023-05-26 19:30 4119

Inspire Healthcare and Toei Shinyaku Unveil 'King Agaricus 100': An All-Natural Supplement for Immunity Support and Cancer Management

SINGAPORE, May 26, 2023 /PRNewswire/ -- Inspire Healthcare, a Singaporean healthcare and biotech start-up, has teamed up withToei Shinyaku to unveil a new supplement specifically formulated to boost immunity and as a complement in cancer management. The supplement,'King Agaricus 100', is the resu...

2023-05-26 15:27 2682

FivepHusion Announces Strategic Collaboration with Treehill Partners and Syneos Health

Supporting FivepHusion's Global Development and Commercialization Strategy SYDNEY, May 26, 2023 /PRNewswire/ -- FivepHusion, an advanced clinical-stage biotechnology company, today announced its collaboration with Treehill Partners, aNew York-based strategic and financial advisory firm specializi...

2023-05-26 13:42 2094

Guizhou uses big data tech to develop smart healthcare

GUIYANG, China, May 26, 2023 /PRNewswire/ -- A news report from Huanqiu.com: "It always took me over half a day to take my child to go to the county and see a doctor for a minor illness several years ago. Now we can get remote diagnosis and treatment services from the higher-level hospital when w...

2023-05-26 11:00 2960

Guizhou uses big data tech to develop smart healthcare

Ascentage Pharma Presents Updated Results from Multiple Clinical Studies at American Society of Clinical Oncology Annual Conference

SUZHOU, China, and ROCKVILLE, Md., May 25, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that 4 of its abstracts were selected for presenta...

2023-05-26 10:01 3004

Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023

* The TORCH-2 study is a Phase I/II trial of the mTORC1/2 inhibitor ATG-008 plus the Anti-PD-1 monoclonal antibody toripalimab for the treatment of patients with advanced solid tumors * The combination treatment produced an objective response rate (ORR ) of 52.4% in the advanced cervical canc...

2023-05-26 09:41 2817

Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis

* Bentrio® meets primary efficacy endpoint in NASAR clinical trial in seasonal allergic rhinitis * Clinically relevant and statistically significant improvement in Total Nasal Symptom Score over saline nasal spray control (p = 0.012) * Bentrio efficacy and tolerability rated as "good" or "ve...

2023-05-26 08:00 3236

Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis

1 ... 149 150 151152153 154 155 ... 808